Patent board rules Sun Pharma claims unpatentable in Biofrontera dispute Feb 26, 2026 09:17AM
FDA accepts BFRI filing for Ameluz skin cancer treatment Feb 11, 2026 09:16AM
Biofrontera reports record Q4 2025 revenues of $17.0-17.5 million Jan 13, 2026 08:30AM
Biofrontera locks databases for actinic keratosis and acne studies Jan 8, 2026 08:46AM
Biofrontera files FDA application for skin cancer treatment Dec 2, 2025 08:45AM


Nov 14, 2025 09:59AM Benchmark Reiterates Buy Rating on Biofrontera (BFRI)
Nov 13, 2025 05:12PM Biofrontera Inc. (BFRI) Misses Q3 EPS by 62c
Nov 7, 2025 08:00AM Biofrontera sells Xepi antibiotic license to Pelthos for up to $10 million
Oct 23, 2025 08:45AM Biofrontera completes acquisition of US assets from former parent
Oct 3, 2025 09:02AM Benchmark Reiterates Buy Rating on Biofrontera (BFRI)
Aug 25, 2025 08:27AM Biofrontera completes Phase 2b acne trial enrollment for Ameluz gel
Jul 1, 2025 09:22AM Biofrontera (BFRI) Will Profit from $11 Million Financing Agreement: Benchmark
Jun 11, 2025 03:01PM Biofrontera Inc. (BFRI) Negotiating Changes to its Cooperation with Biofrontera AG
Jun 3, 2025 02:30PM Biofrontera Inc. (BFRI) Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
May 19, 2025 09:20AM Biofrontera (BFRI) PT Lowered to $2.75 at Benchmark
May 16, 2025 06:57AM Biofrontera Inc. (BFRI) Misses Q1 EPS by 47c
May 15, 2025 12:17PM Biofrontera (BFRI) Announces New Patent Protection on Ameluz until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz
May 6, 2025 12:45PM Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
Mar 24, 2025 08:55AM Benchmark Reiterates Buy Rating on Biofrontera (BFRI)
Jan 8, 2025 09:51AM Biofrontera (BFRI) Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz-Photodynamic Therapy In The Treatment Of Superficial Basal Cell Carcinoma
Dec 23, 2024 09:31AM Biofrontera Inc. (BFRI) Announces 100 RhodoLED XL Machines Now Placed in US Market
Dec 3, 2024 11:00AM Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
Nov 13, 2024 05:45PM Biofrontera Inc. (BFRI) Misses Q3 EPS by 98c
Nov 1, 2024 11:55AM Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
Oct 31, 2024 10:33AM Biofrontera Inc. (BFRI) Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma
Oct 14, 2024 10:30AM Biofrontera (BFRI) Announces Database Lock Of Phase 3 Study Of Ameluz-Photodynamic Therapy In The Treatment Of sBCC
Oct 7, 2024 02:04PM Roth/MKM Reiterates Buy Rating on Biofrontera (BFRI)
Oct 7, 2024 08:45AM Biofrontera (BFRI): FDA Approves Use of Up To Three Tubes of Ameluz Topical Gel, 10% In One Treatment
Sep 25, 2024 10:45AM Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
Aug 15, 2024 01:44PM Biofrontera (BFRI) PT Lowered to $16 at Roth/MKM
Aug 15, 2024 06:43AM Biofrontera Inc. (BFRI) Misses Q2 EPS by 5c
Aug 9, 2024 10:00AM Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
Jun 24, 2024 11:55AM Roth/MKM Reiterates Buy Rating on Biofrontera (BFRI)